Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2016 - 2026)

Gyre Therapeutics has reported Total Non-Current Liabilities over the past 9 years, most recently at $22.4 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 36.81% to $22.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Dec 2025, up 36.81% year-over-year, with the annual reading at $22.4 million for FY2025, 36.81% up from the prior year.
  • Total Non-Current Liabilities was $22.4 million for Q4 2025 at Gyre Therapeutics, up from $18.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $33.3 million in Q4 2023 and troughed at $1.8 million in Q3 2023.
  • The 4-year median for Total Non-Current Liabilities is $17.1 million (2024), against an average of $16.3 million.
  • The largest YoY upside for Total Non-Current Liabilities was 1239.05% in 2024 against a maximum downside of 50.89% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $12.5 million in 2022, then surged by 167.15% to $33.3 million in 2023, then plummeted by 50.89% to $16.4 million in 2024, then surged by 36.81% to $22.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Total Non-Current Liabilities are $22.4 million (Q4 2025), $18.7 million (Q3 2025), and $20.0 million (Q2 2025).